Influence of ursodeoxycholic acid on insulin resistance in patients with metabolic syndrome

Main Article Content

V.I. Pankiv


The lecture describes the mechanisms of non-alcoholic fatty liver disease in patients with metabolic syndrome. A comprehensive treatment with the use of ursodeoxycholic acid has reduced the severity of hepatic steatosis, manifestations of dyslipidemia, the syndromes of cytolysis and cholestasis, the abnormalities of carbohydrate metabolism in patients with me­tabolic syndrome, and, consequently, has positively influenced insulin resistance.

Article Details

How to Cite
Pankiv, V. “Influence of Ursodeoxycholic Acid on Insulin Resistance in Patients With Metabolic Syndrome”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 3, Apr. 2018, pp. 263-7, doi:10.22141/2224-0721.14.3.2018.136424.
To practicing Endocrinologists


Bueverov АО. Possibilities of clinical application of ursodeoxycholic acid. Consilium medicum. 2005;7(6):28-34.

Viriasova OV, Dement'eva RE. New aspects of using ursodeoxycholic acid in cardiology. Vestnik of Penza state university. 2015;(11):123-127.

Maev IV, Kucheriavyi IuA, Morozov SV, et al. Efficiency and tolerability of ursodeoxycholic acid as monotherapy and in combination with lactulose in patients with non-alcoholic steatohepatitis. Klinicheskie perspektivy gastroenterologii, gepatologii. 2012;(2):3-12.

Radchenko ОМ. Ursodeoxycholic acid: achievements, prospects and problems of application. Racional'na farmakoterapija. 2012;(23):28-32.

Tanchenko OA, Naryshkina SV, Sivyakova ON. Ursodeoxycholic acid in complex treatment of metabolic syndrome. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2010;22(1):82-86.

Harchenko NV, Anohina SV, Bojko SV. New approaches to the correction of lipid metabolism disorders in patients with metabolic syndrome. Modern gastroenterology. 2006;(27):36-39.

Oh AR, Bae JS, Lee J, et al. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice BMB Rep. 2016 Feb;49(2):105-10. doi: 10.5483/BMBRep.2016.49.2.173.

Pathil A1, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012 May;55(5):1369-78. doi: 10.1002/hep.25531.

Troisi G, Crisciotti F, Gianturco V, et al. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. Clin Ter. 2013 May-Jun;164(3):203-7. doi: 10.7417/CT.2013.1550.

Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism. 2012 Jul;61(7):944-53. doi: 10.1016/j.metabol.2011.10.023.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>